Introduction
============

The Hpo pathway, a novel signaling pathway defined in drosophila, is extremely powerful in the regulation of growth and the suppression of tumors because of its ability to simultaneously inhibit cell proliferation and promote apoptosis [@B1]-[@B4]. Activation of the pathway induces a kinase cascade in which the Ste20-type kinase Hpo forms a complex with the WW-domain-containing adaptor protein Salvador (Sav). This complex then phosphorylates and activates the NDR family kinase Warts (Wts). After Wts binds to the Mob family protein Mats, it phosphorylates and inactivates the transcriptional co-activator Yorkie (Yki), which binds to the YEAD/TEF factor Scalloped (Sd) and other possible transcription factors to regulate the transcription of cell- cycle and cell-death regulators such as *cyclin E* and *diap 1* [@B5], [@B6]. Like drosophila studies, genetic and cell culture studies in mammalian cells have also linked the Hpo kinase cascade to the phosphorylation of YAP/TAZ, to two mammalian homologs of Yki, (transcriptional co-activator with PDZ-binding motif; also known as WWTR1), and to the regulation of growth [@B7]-[@B13].

The ease of creating genetic mosaics in drosophila has exactly circumvented the hindrance of early lethality following gene depletion in the Hpo signal transduction pathway [@B4]. However, such efforts cannot lead to complete understanding of its in vivo function in early embryonic development. Because of its semitransparent body, genetics and ease of manipulation, zebrafish are considered an ideal vertebrate model for the study of early development and cancer-related genes [@B14], [@B15]. Increasing amount of evidence suggest that the Hpo pathway might be evolutionarily conserved in zebrafish [@B16]-[@B20]. Bioinformatics analyses have indicated a considerable amount of evolutionary conservation between zebrafish and other species in the sequences, domains and motifs of several Hpo pathway components, including YAP/TAZ, LATS, Mats, and Fat [@B16]-[@B22]. Mats1, which regulates cell proliferation, apoptosis, and growth, is evolutionary conserved between zebrafish and drosophila [@B17]. Depletion of zebrafish *yap* ameliorates the changes in pronephros development caused by Fat1 knockdown [@B18]. To further elucidate the effects of the components of the hippo signaling pathway on early embryonic development, we investigated the role of *yap* in the zebrafish embryogenesis. We found that zebrafish *yap* regulates cell proliferation and survival and that it is required for normal formation of the dorsoventral axis.

Results
=======

Embryos depleted of Yap exhibit a phenotype of delayed general development
--------------------------------------------------------------------------

To determine the role of *yap* during zebrafish embryogenesis, a translation-blocking morpholino (*yap*-MO) and a splicing-blocking morpholino (*yap*-MO(S)) were designed to knock down *yap* expression (Fig. [1](#F1){ref-type="fig"}A). The efficacy and specificity of *yap*-MO was recently confirmed [@B19]. We performed RT-PCR to demonstrate the activity of *yap*-MO(S). Our result showed that *yap* mRNA splicing was completely disrupted in embryos injected with 20 ng of the *yap-MO*(S). They either lacked exon2 or had an additional 71 bp fragment in intron2 (Fig. [1](#F1){ref-type="fig"}B). To produce the same phenotype, we used a much higher dose of *yap*-MO(S) than *yap*-MO. We also confirmed the knockdown of endogenous Yap protein by Western blotting (Fig. [1](#F1){ref-type="fig"}C).

Almost all *yap*-MO-injected embryos showed a phenotype of delayed development, defined by comparison to age-matched control embryos (Fig. [2](#F2){ref-type="fig"}A-D and A\'-D\'). At 24 hpf, 51% of these abnormal *yap*-MO morphants (2-5 ng of *yap*-MO per embryo) showed moderate deviation from the morphological norm (Fig. [1](#F1){ref-type="fig"}D-c, c\', and E), 26% with mild morphological abnormality (Fig. [1](#F1){ref-type="fig"}D-b, b\', and E), and the rest 23% showed severe morphological deviations (Fig. [1](#F1){ref-type="fig"}D-d, d\', and E). Mild morphants has indistinct heads and tails that bent toward the abdomen, moderate morphants had short bodies and curved trunks, and severe morphants had small trunks and completely indistinct bodies. Mortality was calculated at 48 hpf (Fig. [1](#F1){ref-type="fig"}E). No death was detected in the mild group (0/24). There was a 52% death rate in the moderate group (25/48) and a 64% death rate in the severe group (14/22). This effect was found to be MO-concentration-dependent (Table [1](#T1){ref-type="table"}). Previous work has shown that embryos with reduced Yap exhibit marked increase in cell death of brain at 24 hpf [@B19]. In this study, we examined *yap*-MO-injected embryos at multiple time points during the first 24 h of development and compared them with their wild-type siblings (Fig. [2](#F2){ref-type="fig"}). At 6 hpf, when con-MO-injected or wild-type siblings reached the 60%-epiboly stage, the *yap* morphants had only developed to about the 50%-epiboly stage. The germ ring appeared thicker than that of wild-type (Fig. [2](#F2){ref-type="fig"}A and A\'). At 10 hpf. The epiboly of siblings injected with con-MO was already complete but *yap* morphants showed only 60-80% epiboly (Fig. [2](#F2){ref-type="fig"}B and B\'). By 18 hpf, the yolk extension of con-MO-injected siblings was clearly delimited from the yolk ball as the tail had straightened out, but the *yap* morphants were developmentally equivalent to wild-type or control embryos at about 14 hpf (Fig. [2](#F2){ref-type="fig"}C and C\'). At 24 hpf, *yap*-MO-injected embryos displayed a shortened body axis and notable opacity in the head (Fig. [2](#F2){ref-type="fig"}D and D\').

Both *zyap1* and *zyap2* partially rescued the phenotype of *yap* morphants
---------------------------------------------------------------------------

During sequencing of the expression vector of synthetic *yap*-mRNA, we found a splicing variant that encodes zebradfish Yap with the first WW-domain. Yap with two WW-domains, known preciously as zebrafish Yap, is here designated as Yap2 and the new Yap, which has only one WW-domain, is here designated as Yap1. Yap1 differs from Yap 2 in that it lacks the WW domain encoded on fourth exon. Yap2 may be a splicing variant ([Supplementary Material](#SM1){ref-type="supplementary-material"}: Fig. S1). The fourth exon is downstream of and far away from the target region of *yap*-MO(S). This is why *yap*-MO(S) can disrupt normal splicing (Fig. [1](#F1){ref-type="fig"}A, B). We injected zebrafish *yap1* (*zyap1*) and *yap2* (*zyap2*) mRNA, both lacking the targeted 5\'-UTR, into different individuals. The phenotypes of the resulting *yap* MO morphants were partially rescued by con injection of *yap* mRNA (Fig. [2](#F2){ref-type="fig"}A\'\'- D"). We counted the number of both moderate and severe embryo in each group at 24 hpf and found no obvious differences between yap1 and yap2 with respect to rescue (Fig. [3](#F3){ref-type="fig"}).

Both cell survival and proliferation are defective in *yap* morphant embryos
----------------------------------------------------------------------------

Yki/*YAP* is a potent promoter of cell survival and proliferation in drosophila and a variety of cultured mammalian cells [@B1]-[@B4], [@B7]-[@B12], and is inhibited by Hpo signaling. To determine whether knocking down of *yap* increases the rate of apoptosis in developing vertebrate embryos, a TUNEL assay was performed during the first 24 hpf (Fig. [4](#F4){ref-type="fig"}A-D and A\'-D\'). Both the control embryos and *yap* morphant embryos showed no or few TUNEL-positive signaling at 6 and 10 hpf (Fig. [4](#F4){ref-type="fig"}A, A\', B, and B\'). This may be because apoptotic cell death rarely occurs before 10 hpf. The *yap*-MO-injected embryos clearly exhibited increased apoptosis at 18 and 24 hpf, mainly in the head and caudal parts (Fig. [4](#F4){ref-type="fig"}C, C\', D, and D\'). In this way, knockdown of *yap* was found to result in increased cell death during embryonic development.

Then we determined whether cell proliferation in *yap* morphant embryos was defective. We used phosphohistone H3 (PH3) antibody staining to mark M-phase cells (Fig. [4](#F4){ref-type="fig"}E-H and E\'-H\'). At earlier stages (6, 10, and 18 hpf), the *yap* morphant embryos showed fewer mitotic cells than control or wild-type siblings (Fig. [4](#F4){ref-type="fig"}E,E\', F, F\', G, and G\'). However, at 24 hpf, no significant difference in the PH3 staining was found between *yap* morphants and control embryos (Fig. [4](#F4){ref-type="fig"}H and H\'). This is consistent with the results of our fluorescence-activated cell sorting (FACS) analysis (data not shown).

Disrupted dorsoventral patterning in*yap*-depleted embryos
----------------------------------------------------------

To determine whether *yap* inhibition affects markers of dorsoventral patterning during early stages of development, we examined the expression of various ventral and dorsal markers during early and late gastrula stages. There was no obvious difference in spatial expression of the ventral marker*bmp2b* between *yap* morphant and control embryos (Fig. [5](#F5){ref-type="fig"}A and A\') [@B23], although there appeared to be a clear overall delay in the development of age-matched morphants relative to control and wild-type siblings. Defective epiboly movement during gastrulation may be the direct cause of the delayed development and similar spatial expression. The same may be true of the absence of dorsal markers *no tail (ntl)* (Fig. [5](#F5){ref-type="fig"}D, D\', E, and E\') and the presence of *foxA2* (Fig. [5](#F5){ref-type="fig"}F and F\') [@B24]-[@B26]. However, the control expression profiles of *gsc* and *gata2* during gastrulation showed reduced *gsc* expression in the prechordal plate and increased *gata2* expression in the ventral mesoderm rather than a simple delayed pattern (Fig. [5](#F5){ref-type="fig"}B, B\', C, and C\') [@B27]-[@B29]. In total, these data suggested that the reduction of *yap* disrupted dorsoventral marker expression during zebrafish gastrulation.

Effects of zebrafish *yap* on somitogenesis
-------------------------------------------

Both the expression pattern of *yap* during somitogenesis and the shortened body axis of *yap*-depleted embryos indicate that *yap* function is critical for somatic development [@B19]. For this reason, we examined the expression of somatic marker *myoD* [@B30] in control and *yap*morphants. In situ hybridization showed that the level of *myoD* transcription might be up-regulated in *yap*-depleted embryos relative to control embryos (Fig. [6](#F6){ref-type="fig"}C and D). To confirm this result, we performed real-time PCR to quantify *myoD* expression level at 18hpf. We found a 2-fold increase of *myoD* mRNA level in *yap*-morphants compared with control (Fig. [6](#F6){ref-type="fig"}I). Despite the delayed onset of somatic development, somitogenesis proceeded faster in *yap* morphant embryos than that of the control, and *yap*-depleted embryos and control siblings reached the 18-somite stage at the same time (Fig. [6](#F6){ref-type="fig"}A-D).*titin* marks a somatic border in zebrafish embryos [@B31]. In control embryos, the dorsal and ventral portions of each myotome converge at the point where the horizontal myoseptum forms, and the somites take on a v-shape (Fig. [6](#F6){ref-type="fig"}E and G). In contrast, the somites in *yap*-MO-injected embryos appeared U-shaped (Fig. [6](#F6){ref-type="fig"}F and H) [@B32]. These results indicate that *yap* morphants have a higher expression level of *myoD*.

Delayed cardiogenesis and hematopoiesis in *yap*-MO-injected embryos
--------------------------------------------------------------------

Knockdown of *yap* causes developmental delay of cardiogenesis and hematopoiesis. In situ hybridization at 24 hpf with cardiac-specific markers *nkx2.5* and *titin* has demonstrated that the heart primordia in *yap*-MO-injected embryo forms a shallow cone with its apex raised dorsally around the lumen, but the primordia of control embryos had already transformed into a linear tube (Fig. [7](#F7){ref-type="fig"}A, A\', B, and B\') [@B30], [@B33]. However, there was no observable difference in the timing of blood vessel development between *yap* morphants and control embryos, as assessed using the vascular marker *flk-1* (Fig.[7](#F7){ref-type="fig"}C and C\') [@B34].

Erythrocytes in 30 hpf and 52 hpf embyos were identified by o-dianisdine staining (Fig. [8](#F8){ref-type="fig"}I), in which the presence of hemoglobin in erythrocytes was shown by a brown color after staining [@B35]. *yap*-MO embryos showed no red blood cells (RBC) at 30 hpf, but it was significantly recovered at 52 hpf. Further analysis of the *yap* morphant phenotype in Tg(*gata1*:EGFP) fish showed a clear delay in hematopoiesis after 28 hpf (Fig.8II). Overall, our data indicate that *yap*-MO-injected embryos experience delayed cardiogenesis and hematopoiesis.

RT-PCR and real-time PCR analysis for candidate target genes of the zebrafish Hpo signaling pathway
---------------------------------------------------------------------------------------------------

In drosophila and murine livers, several genes have been shown to be targets of the Hpo pathway. These include the cell-cycle regulator cyclin E (*ccne*) and cell-death regulator Diap1 \[11.36\]. To further investigate the mechanism by which the zebrafish Hpo pathway coordinately regulates call proliferation and apoptosis, we searched the updated zebrafish proteome database (<http://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastp&BLAST_PROGRAMS=blastp&PAGE_TYPE=BlastSearch&SHOW_DEFAULTS=on&LINK_LOC=blasthome>) for candidate target genes of Hpo pathway. Based on sequence similarity, we selected six candidate downstream targets of Hpo pathway to validate using RT-PCR analysis, including *ccne1*, *ccne2*, *ccnd1*, *birc2*, *xiap*, and *ciapin*. We found that the transcriptional level of *ccne2* was down-regulated in *yap*-depleted embryos (Fig. [9](#F9){ref-type="fig"}I). Real-time PCR was used to further confirm the results of RT-PCR (Fig. 9II). In addition, Hpo has been shown to phosphorylate and destabilized Diap1 through non-transcriptional processes [@B37], [@B38]. This is one possible explanation for the lack of marked changes in transcriptional level of these three possible regulators of cell death. In addition, undetected inhibitors of apoptosis may also have been involved in this process.

In mammalian cells, Lats can regulate the activity of TAZ, which shares sequence similarity to YAP and modulates mesenchymal differentiation [@B13]. In addition, TAZ-deficient zebrafish embryos were found to be defective in bone formation, as in our previous report on the phenotype of *yap*-MO-injected embryos [@B39]. For this reason, we determined expression level of TAZ in *yap*-morphants. We found that the same level of TAZ transcripts was present in *yap*-depleted embryos and in controls (Fig. [9](#F9){ref-type="fig"}I), ruling out the possibility that *yap*-MO produced these RT-PCR results and delayed phenotypes by reducing the level of TAZ.

Discussion
==========

Previous analysis of the sequence and conservation of the domains of core components of the Hpo pathway have facilitated in-depth investigations on the role of this signaling pathway during zebrafish early embryogenesis [@B16]-[@B20]. Our previous works have shown that *yap* knockdown caused morphological defects, including small heads, small eyes, and less cartilage in the branchial arches [@B19]. In this study, the difination of increased cell apoptosis and decreased cell proliferation may be the direct explanation of these morphological defects. Otherwise, we demonstrated that *yap*-mediated signaling establish specific dorsoventral patterning in zebrafish. Reduction of *yap* expression was also found to severely delay several developmental events, such as gastrulation, cardiogenesis, and hematopoiesis.

In this study, we tested the efficacy of both the translation-blocking *yap*-MO [@B19] and the splice-blocking *yap*-MO(S) (Fig.[1](#F1){ref-type="fig"}B) by RT-PCR and Western blotting. Our results indicate that both MOs are effective to knock down the endogenous Yap protein, albeit we need to use a higher dose of the *yap MO(S)* (20 ng). Although we showed a disrupted *yap* mRNA-splicing in the 20 ng yap MO(S) group by RT-PCR, there was still a small amount of Yap protein present in the morphants as shown by western blotting. It is likely that either our RT-PCR is not sensitive enough, or there are still some maternal Yap proteins present at this stage.

Yap gain of function causes shortened body axis and perturbed somatic and head morphology in both zebrafish and xenopus [@B20]. Because these late morphologies are similar to the *yap* knocking down phenotype, it can be difficult to determine whether the rescue is caused by overexpression of *yap* or knocking down of *yap*. The ratio of *yap* MO to *yap* mRNA needs more experimentation to be determined.

As previously reported, zebrafish Yap (Yap2), like mouse and human YAPs, contains two WW domains. We have identified the one WW domain splicing variant in zebrafish (Yap1). Zebrafish Yaps share significant sequence similarity with their homologues from chickens, mice, and humans ([Supplementary Material](#SM1){ref-type="supplementary-material"}: Fig. S2). This is especially true of the YAP2s of humans, mice, and zebrafish. Human YAP, which has two WW-domains, is a more potent transcriptional co-activator when compared with YAP with only one WW-domain [@B40]. In mice, both YAPs have two WW-domains. The first WW-domain has more pronounced affinity for the PPxY sequence, to which it binds more strongly than the second WW-domain does [@B41]. Although the functions of zebrafish Yap1 and each WW domain of Yap2 are still unknown, the determination of the precise differences in signaling among *yap* splicing variants might be important.

During gastrulation, overall developmental delay increases the difficulty of analyzing defective dorsoventral patterns in *yap*-MO-injected embryos, but *yap* knockdown does reduce *gsc* expression and increase *gata2* expression. Confirmation of *gsc* down-regulation showed that *yap*-depleted embryos had up-regulated levels of *myoD* at 18 hpf with small heads. This is consistent with a previously described pattern in *gsc*-depleted xenopus embryos [@B42]. *yap*-depleted embryos seem to develop a ventralized morphology. During the cell fate specification phase of mouse trophectoderm (TE) development, the Hpo signaling pathway components Lats and Yap increase Tead4 activity, which induces Cdx2 expression by overcoming Oct3/4-mediated suppression [@B43]. Maternal zebrafish Spg/Pou2/Oct4 controls the formation of the vertebrate dorsoventral axis and the *spg/pou2/oct4* mutant embryos develop a dorsalized morphology [@B44]. This is in contrast to our ventralized *yap* morphants, raising the possibility that Yap is required to establish dorsoventral patterning and that it does so by overcoming Spg/Pou2/Oct4-mediated suppression. Further elucidation of the mechanisms by which Yap controls dorsoventral axis formation are required for a more complete understanding of maternal control of embryonic development.

Conclusion
==========

In conclusion, zebrafish *yap* is required during early embryonic development. Reduction of *yap* leads to increased apoptosis, decreased proliferation, disrupted dorsoventral patterns and somitogenesis, as well as delayed cardiogenesis and hematopoiesis. Full identification of zYAP2 and further analysis of *yap* function are essential to understanding the function of the Hippo signaling pathway in zebrafish embryonic development.

Materials and methods
=====================

Fish care
---------

The maintenance, breeding, and staging of zebrafish lines (AB and Shanghai) were performed as described previously [@B45], [@B46]. The *Tg(gata1:EGFP)* zebrafish line used in this study has been described elsewhere [@B47].

Morpholinos and microinjection
------------------------------

Morpholino (MO) antisense oligonucleotides *yap*-MO (5′-CTCTTCTTTCTATCCAACAGAAACC-3′), *yap*-MO(S) (5′-GCAACATTAACAACTCACTTTAGGA-3′), and con-MO (5′-CCTCTTACCTCAGTTACAATTTATA-3′) were obtained from Gene Tools, LLC (U.S.). One- and two-cell stage wildtype and *Tg(gata1:EGFP)* zebrafish embryos were injected with MOs (2-5 ng/embryo).

Whole-mount TUNEL (terminal deoxynucleotide transferase mediated dUTP nick-end labeling) staining
-------------------------------------------------------------------------------------------------

Embryos were fixed in 4% PFA overnight at 4°C, then rinsed in PBS before proceeding with whole-mount TUNEL staining using an in situ Cell Death Detection Kit (Roche) according to the manufacturer\'s instructions.

Whole-mount PH3 antibody staining
---------------------------------

Mitotic cells were stained with a rabbit polyclonal anti phospho-histone H3 (Ser10) antibody (Cell Signaling Technology, Inc.). This was performed almost exactly as described in *The Zebrafish Book* at a dilution of 1:1000 [@B46]. The secondary antibody rhodamine (TRITC)-conjugated goat anti-rabbit IgG (Southern Biotech, U.S.) was diluted at 1:200.

Whole-mount in situ hybridization
---------------------------------

Digoxigenin-labeled antisense RNA probes for zebrafish *bmp2b*,*gsc*,*ntl*,*foxA2*, *gata2*,*myoD*,*titin*,*nkx2.5*, and*flk-1* were synthesized as described in previously published studies. Whole-mount in situ hybridization assay was performed as described [@B48].

O-dianisidine staining for globin
---------------------------------

Embryos were dechorionated and fixed in 4% PFA overnight at 4°C, then rinsed in PBS before proceeding with o-dianisdine staining. Fixed embryos were incubated in the staining buffer for 15 min in the dark. The staining buffer consisted of 0.6 mg/ml o-dianisidine (Sigma), 10 mM sodium acetate, 0.65% hydrogen peroxide, and 40% (v/v) ethanol.

Reverse transcription-polymerase chain reaction (RT-PCR) and quantitative RT-PCR
--------------------------------------------------------------------------------

Total RNA was extracted from zebrafish embryos using the Trizol reagent (Invitrogen) according to the manufacturer\'s protocol. Complimentary DNA synthesis was performed using a standard protocol with oligo-dT primers and Moloney murine leukemia virus reverse transcriptase (TaKaRa).

Primers (Table [2](#T2){ref-type="table"}) were designed using PRIMER 3 software. PCR conditions were as follows: 95°C for 6 min; 30 cycles of 94°C for 30 s; 53°C for 30 s; and 72°C for 45 s; then 72°C for 10 min. The products were stored at 4°C. PCR products were separated on a 1.5% agarose gel.

Quantitative RT-PCR was performed on the 7500 (ABI) using the SYBR Premix Ex Taq (TaKaRa). Measurements were performed in quadruplicate and normalized to the expression levels of Elf1-α. Fold changes values (X) were calculated using the following formula: X=2^-ΔΔCt^. Bars indicate standard deviations. The PCR cycling conditions were as follows: 40 cycles of pre-denaturation at 95°C for 30 s, denaturation at 95°C for 5 s, and annealing and extension at 60°C for 34 s.

Protein extraction and Western blot analysis
--------------------------------------------

Total proteins were extracted from zebrafish embryos using RIPA solutions (Cell Signaling Technology, Inc.) according to the manufacturer\'s protocol. Protein concentrations were determined using the Bradford assay (BioRad). The proteins were then resolved on SDS/polyacrylamide gels and transferred to polyvinylidene fluoride membranes (Millipore). The membranes were probed with the following primary antibodies: YAP1 (Proteintech) and β-actin (Cell Signaling Technology, Inc.). After further washes, the membranes were incubated with the appropriate horseradish peroxidase-conjugated secondary antibodies (Proteintech). Blots were developed using ECL (Millipore).
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![**Analysis of *yap*-MOs and *yap* morphant phenotype.**A) Structure of zebrafish *yap* pre-mRNA (up) and mature mRNA (down). The black lines represent introns, the black rectangles represent exons, and the white rectangles represent untranslated regions (UTR). *yap*-MO(S) binds to the exon2-intron2 boundary and *yap*-MO binds to the 5′UTR near the ATG site. The blue rectangular dashed lines represent the WW-domain, which has here been omitted. B) RT-PCR analysis of *yap*-MO(S). RT-PCR was performed with a pair of primers (green arrows in (A), Table [1](#T1){ref-type="table"}). C) Western blot analysis of *yap*-MO and *yap*-MO(S). Total proteins were extracted from 24 hpf zebrafish embryos. D) Bright-field images of 24 hpf embryos injected with con-MO (2-5 ng/embryo) (a and a′) and *yap*-MO (2-5 ng/embryo) (b-d, b′-d′). At 24 hpf, *yap* morphants was divided into three groups according to their phenotypes: wild (b and b′), moderate (c and c′) and severe (d and d′). D) The horizontal bars show the distribution of phenotypes observed in (C), and the vertical bars represent the death rate of each group before 48 hpf.](ijbsv09p0267g01){#F1}

![**Phenotypes of*yap* morphant and rescued phenotype.**A-D) and A′-D′) Bright-field images show *yap* morphants, all of which exhibited developmental delay. A′′-D′′) This phenotype could be partially rescued after injection of synthesized *yap*-mRNA.](ijbsv09p0267g02){#F2}

![**No obvious differences between zyap1 and zyap2 with respect to rescue.**The percentage of abnormally developed embryos among control embryos, *yap* morphants, and *yap*-mRNA rescued morphants. The synthetic *yap*-mRNAs were found to partially rescue the *yap*-MO phenotype.](ijbsv09p0267g03){#F3}

![**Role of *yap* in regulation of apoptosis and proliferation during the first 24 hpf**. A-D) and A′-D′) TUNEL staining indicates that knockdown of *yap* leads to increased cell death in the head and caudal parts. E-H) and E′-H′) PH3 antibody staining suggests that *yap* inhibition results in reduced cell proliferation.](ijbsv09p0267g04){#F4}

![**Analysis of dorsoventral markers in *yap* morphants during gastrulation.**A-F) and A′-F′) Whole-mount in situ hybridization of 6-9.5 hpf embryos injected with 2-5 ng con-MO (A-F) and *yap*-MO (A\'-F\') for *bmp2b* (A and A′), *gata2* (B and B′), *gsc* (C and C′), *ntl* (D, D′, E and E′), and *foxA2* (F and F′). Embryos are shown laterally with ventral to the left (A-C and A′-C′), dorsally with anterior to the top (D, D′, F and F′), and vegetally with ventral to the top (E and E′).](ijbsv09p0267g05){#F5}

![**Effect of zebrafish *yap* on somitogenesis.**A-H) Whole-mount in situ hybridization for (A-D) *myoD* and (E-H) *titin* at 12, 18, and 24 hpf. A-D) Dorsal view with head to the left. E-H) Lateral view with head to the left. C, D, G, and H) The insets (bottom left corner) show the corresponding whole embryos. I) Real-time PCR result for *myoD expression*.](ijbsv09p0267g06){#F6}

![**Delayed cardiogenesis and normal vasculogenesis in *yap* morphants.**A-C and A′-C′) Whole-mount in situ hybridization with *nkx2.5, titin*, and *flk-1*. A, A′, B, and B′) Anterior view with dorsal to the top. C and C′) Lateral view with head to the left.](ijbsv09p0267g07){#F7}

![**Delayed hematopoiesis in *yap* morphants.**I) O-dianisdine staining shows that *yap*-MO embryos (B) have no red blood cells (RBC) at 30 hpf, with (D) significant recovery by 52 hpf. II) (A-J) Bright-field image and (A′-J′) fluorescent image of live *Tg(gata1:EGFP)* embryos with (A, A′, B, B′, E, E′, G, G′, I, and I′) *con-MO* and (C, C′, D, D′, F, F′, H, H′, J, and J′) *yap*-MO. A-J and A′-J′) Lateral view with head to the left, except in B, B′, D, and D′ (posterior view with dorsal to the top).](ijbsv09p0267g08){#F8}

![**RT-PCR and realtime-PCR analysis for candidate target genes of zebrafish Hpo signaling pathway.** I) For each gene (*ccne*, *ccne2*, *ccnd1*, *birc2*, *xiap*, *ciapin*, and *taz*), relative expression based on the RT-PCR is shown. Total mRNA was extracted from 18 hpf *yap*-MO and con-MO embryos, respectively. *ef-1a* was used as a loading control. II) Real-time-PCR result for *ccne2*, *ccnd1*, *birc2*, and *ciapin*.](ijbsv09p0267g09){#F9}

###### 

Phenotypes observed in subjects exposed to different concentrations of *yap*-MO.

                       n     Phenotype                                           
  -------------------- ----- ------------ ------------ ------------ ------------ -------------
  con-MO               100   96 (96.0%)   4 (4.0%)     0 (0.0%)     0 (0.0%)     2 (2.00%)
  0.25-1 ng *yap*-MO   102   26 (25.5%)   55 (53.9%)   20 (19.6%)   1 (1%)       11 (10.78%)
  2-5 ng *yap*-MO      99    0 (0.0%)     23 (23.2%)   51 (51.5%)   25 (25.3%)   43 (43.43%)
  10-15 ng *yap*-MO    101   0 (0.0%)     2 (2.0%)     29 (28.7%)   70 (69.3%)   61 (60.39%)

###### 

Primer sequences.

  Gene product   Gene bank ID     Upstream primers (5′\>3′)   Downstream primers (5′\>3′)   Product size (bp)
  -------------- ---------------- --------------------------- ----------------------------- -------------------
  *ccne*         NM_130995.1      cgcagtgctgactgatgaat        actcgagtccccatgacaac          422
  *ccne2*        NM_001002075.1   cacgacaagagcttcatcca        aggtttcctgcgagaactga          439
  *ccnd1*        NM_131025.2      cccaccatctgaccaatacc        gaaaaagcagggagcacttg          410
  *birc2*        NM_194395.2      catcataggggaaggaagca        ccttacaacacgcctggatt          438
  *xiap*         NM_194396.2      atggcgaattggaatctgac        atggcgaattggaatctgac          408
  *ciapin*       NM_001003738.1   tgcctccagctatgactgtg        tgcatccaaaagagcatctg          490
  *taz*          NM_001037696.1   aacagtgggccgtatcactc        tgagagcacaaatccgacag          415
  *ef-1a*        NM_131263.1      cttcgtcccaatttcaggat        cagagactcgtggtgcatct          300
  *myoD*         NM_131262.2      cgaggtcctgcgaattttag        ctggggtccaagtcttcaaa          273
  *yap-sp*       NM_001139480.1   ggttgagaaagctgccagac        tgggaaccttgctttactgg          583
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